These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12121952)

  • 21. Influence of the decrease in ciprofloxacin susceptibility and the presence of human serum on the in vitro susceptibility of Streptococcus pneumoniae to five new quinolones.
    Balcabao IP; Alou L; Aguilar L; Gomez-Lus ML; Giménez MJ; Prieto J
    J Antimicrob Chemother; 2001 Dec; 48(6):907-9. PubMed ID: 11733477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.
    White RL; Enzweiler KA; Friedrich LV; Wagner D; Hoban D; Bosso JA
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):207-17. PubMed ID: 12106954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The susceptibility of Streptococcus pneumoniae to levofloxacin and other antibiotics.
    Keller N; Smollen G; Davidson Y; Barzilai A; Keren G; Rubinstein E
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():1-3. PubMed ID: 10404329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
    Johnson AP; Warner M; Livermore DM
    Int J Antimicrob Agents; 2001 May; 17(5):377-81. PubMed ID: 11337224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.
    Adam HJ; Schurek KN; Decorby MR; Weshnoweski B; Vashisht R; Karlowsky K; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2006 Jul; 58(1):202-4. PubMed ID: 16636082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian Bacterial Surveillance Network.
    Buxbaum A; Straschil U; Moser C; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 1999 May; 43 Suppl B():13-8. PubMed ID: 10382870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in ciprofloxacin nonsusceptibility and levofloxacin resistance among Streptococcus pneumoniae isolates in North America.
    Karlowsky JA; Nealy L; Sahm DF; Thornsberry C; Jones ME
    J Clin Microbiol; 2001 Jul; 39(7):2748-50. PubMed ID: 11446362
    [No Abstract]   [Full Text] [Related]  

  • 29. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
    Drugeon HB; Juvin ME; Bryskier A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():55-9. PubMed ID: 10404339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season.
    Jones RN; Pfaller MA; Doern GV
    Diagn Microbiol Infect Dis; 1998 Oct; 32(2):119-26. PubMed ID: 9823536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.
    Ho PL; Yung RW; Tsang DN; Que TL; Ho M; Seto WH; Ng TK; Yam WC; Ng WW
    J Antimicrob Chemother; 2001 Nov; 48(5):659-65. PubMed ID: 11679555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales.
    Johnson AP; Warner M; George RC; Livermore DM
    J Antimicrob Chemother; 2001 Apr; 47(4):411-5. PubMed ID: 11266412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
    Lopez H; Vilches V; Scarano S; Stepanik D; Smayevsky J; Lemme L; Cardeñosa O; Ambler J; Sucari A
    Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
    Jones RN; Biedenbach DJ
    Diagn Microbiol Infect Dis; 2003 Apr; 45(4):273-8. PubMed ID: 12729999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States.
    Karlowsky JA; Thornsberry C; Critchley IA; Jones ME; Evangelista AT; Noel GJ; Sahm DF
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1790-7. PubMed ID: 12760850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
    Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.
    Blondeau JM; Vaughan D; Laskowski R; Borsos S;
    Int J Antimicrob Agents; 2001 Jun; 17(6):457-64. PubMed ID: 11397615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program.
    Doern GV; Pfaller MA; Erwin ME; Brueggemann AB; Jones RN
    Diagn Microbiol Infect Dis; 1998 Dec; 32(4):313-6. PubMed ID: 9934549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emergence of penicillin-resistant Streptococcus pneumoniae ocular infections.
    Penland RL; Wilhelmus KR
    Cornea; 1998 Mar; 17(2):135-40. PubMed ID: 9520187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.